Eaglenos Co., Ltd., established in 2017, brings together top talents in chemistry, materials, electronics, software, machinery, biomedical engineering and other fields. Adhering to the core values of "quality, innovation, cooperation and accountability", Eaglenos is committed to the innovation in electrochemistry, microfluidics, signal acquisition and automation technologies. We have launched a series of accurate POCT products for various diseases such as diabetes, hyperuricemia, cardiovascular and cerebrovascular diseases. Eaglenos started its formal operation in June 2018 and has continuously expanded and developed. With an investment of 150 million RMB, the company has an R&D base of over 9,000 square meters in Jiangbei New Area, including international standard R&D labs, GMP production workshops and automated production lines, etc.

Eaglenos (晶捷生物科)

Eaglenos (晶捷生物科)